Pfizer locks employees out of India plant; GSK's Arzerra hit study endpoint;

@FiercePharma: Top news Thurs: What's the gleam in Sanofi CEO's eye? Could be Q2--or a canny PCSK9 maneuver. Article | Follow @FiercePharma

@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. PR, ICYMI. Earnings statement (PDF) | Follow @TracyStaton

@EricPFierce: Amgen CEO says it is turning to new, manufacturing technology. That won't save nearly 500 production jobs. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Miss yesterday's issue of FierceVaccines? Subscribe here | Follow @CarlyHFierce

> Pfizer ($PFE) locked out some employees at a plant in India on Friday, saying that workers had disrupted production lines and threatened some managers. Story

> Pfizer is asking the Nevada Supreme Court to decide if the state's attorney general acted properly by hiring private law firms and agreeing to pay them a contingency fee to handle a case against the drugmaker. Story

> Idenix Pharmaceuticals ($IDIX), which is being bought by Merck ($MRK) for $3.8 billion, reported that it lost about $65 million in the second quarter but has about $178 million in cash on hand. Release

> GlaxoSmithKline ($GSK) said that the Independent Data Monitoring Committee's (IDMC) interim analysis of the PROLONG Phase III study found that its Arzerra hit the primary endpoint of improving progression-free survival in patients with relapsed chronic lymphocytic leukemia (CLL) who responded to treatment at relapse. Release

> European regulators have agreed to undertake an accelerated assessment of Eisai's lenvatinib as a treatment for progressive radioiodine-refractory, differentiated thyroid cancer. Story

> Alexion Pharmaceuticals ($ALXN) announced that the European Commission has granted orphan drug designation (ODD) to Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis (MG). Release

Medical Device News

@FierceMedDev: HeartWare celebrates record Q2 sales despite regulatory pushback. Story | Follow @FierceMedDev

@StacyALawrence: Device share of healthcare venture capital funding hits decade low. More | Follow @StacyALawrence

@VarunSaxena2: FDA announces intention to comprehensively regulate lab-developed tests. Article | Follow @VarunSaxena2

@MichaelGFierce: Nature-inspired artificial cilia could help move drugs to a target. Report | Follow @MichaelGFierce

@EmilyWFierce: Physicians weigh in on Johnson & Johnson's decision to withdraw power morcellator products from the market. More from the NYT | Follow @EmilyWFierce

> FDA announces intention to comprehensively regulate lab-developed tests. Story

> 3D Systems buys surgical virtual reality player for $120M, falls 11% on earnings miss. More

Biotech News

@FierceBiotech: FDA panel green-lights Baxter and Halozyme's drug on a second pass. News | Follow @FierceBiotech

@JohnCFierce: Top story for July: UPDATED: Amgen axing up to 2,900 staffers, shuttering R&D campus in revamp. Article | Follow @JohnCFierce

@DamianFierce: Last thing on priority review vouchers: Creators figured they'd have a market value of up to $500M. and paying just $67.5M. | Follow @DamianFierce

@EmilyMFierce: NIH to launch early Ebola vaccine trial in September. More from USAToday | Follow @EmilyMFierce

> Almirall seeks dermatology deals, Euro biotech IPOs fall short, Cellectis increases CAR-T focus. EuroBiotech report

> Venrock unveils a $450M new fund with eyes on biotech. News

> Sarepta looks to quiet controversy with a boardroom shakeup. Article

And Finally... Attorney General Eric Holder has said states should be open about the drugs used in lethal cocktails after a number of executions have been botched. Story